Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftriaxone to prevent pneumonia after cardiac arrest
NCT04999592Phase 2Terminated
- Start
- Aug 2021
- Primary completion
- Mar 2024
- Modality
- Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised, triple-blind trial of ceftriaxone in pneumonia. Primary endpoint: Clinically-diagnosed Early-onset Pneumonia at 4 days. Started Aug 2021; status: terminated.
02
Drugs
ceftriaxone
03
Conditions
pneumonia
Beyond the preview
Go deeper on NCT04999592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04999592.